Several inhibitors targeting ADAM10 are available, with GI254023X and Aderbasib (INCB7839) as the most advanced examples, the latter tested in a phase II study on breast cancer and currently studied in children with glioblastoma [27, 34, 36, 37, 58] (NCT01254136, NCT04295759). Here, ADAM10 is linked to breast carcinoma.